India Denies Patent for TB Drug Combination, Aiding Generic Manufacturers

TV9 Hindi · health

The Indian Patent Office has rejected a patent application from the US-based TB Alliance for the BPaL therapy, used to treat drug-resistant tuberculosis. This decision, made, prevents any single entity from monopolizing the fixed-dose combination. The move is expected to pave the way for Indian generic drug manufacturers to produce the medication. TB experts view this as a victory for patients, aligning with India's policy to ensure affordable access to essential medicines for serious diseases.